Antibacterial drug discovery in the resistance era

Nature

Volumn 529, Issue 7586, 2016, Pages 336-343

  Brown, Eric D ^a,b   Wright, Gerard D ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANSAMYCIN DERIVATIVE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GLYCOPEPTIDE; KANAMYCIN; LINEZOLID; MACROLIDE; NEOMYCIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; PRISTINAMYCIN; QUINOLONE DERIVATIVE; RIFAMYCIN; SPECTINOMYCIN; STREPTOGRAMIN DERIVATIVE; SULFANILAMIDE; SULFONAMIDE; TEICOPLANIN; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTICS; BACTERIUM; DISEASE CONTROL; DISEASE RESISTANCE; DRUG DEVELOPMENT; RESEARCH WORK;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; CYTOLOGY; ESSENTIAL GENE; GENE INTERACTION; GENOMICS; HUMAN; INFECTION CONTROL; MICROORGANISM; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; BACTERIAL GENE; BACTERIUM; CHEMISTRY; CLASSIFICATION; DRUG DEVELOPMENT; DRUG EFFECTS; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; PROCEDURES; TRENDS;

BACTERIA (MICROORGANISMS);

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; DRUG DISCOVERY; DRUG RESISTANCE, BACTERIAL; GENES, BACTERIAL; GENES, ESSENTIAL; HUMANS;

EID: 84955461306     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature17042     Document Type: Review

References (83)

1. Fleming, A. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae. Br. J. Exp. Pathol. 10, 226-236 (1929).
2. Comroe, J. H. Jr. Pay dirt: the story of streptomycin. Part I. From Waksman to Waksman. Am. Rev. Respir. Dis. 117, 773-781 (1978).
3. Wright, G. D. The antibiotic resistome: the nexus of chemical and genetic diversity. Nature Rev. Microbiol. 5, 175-186 (2007).
4. Perry, J. A., Westman, E. L. & Wright, G. D. The antibiotic resistome: what's new? Curr. Opin. Microbiol. 21, 45-50 (2014).
5. Forsberg, K. J. et al. Bacterial phylogeny structures soil resistomes across habitats. Nature 509, 612-616 (2014).
6. Nesme, J. & Simonet, P. The soil resistome: a critical review on antibiotic resistance origins, ecology and dissemination potential in telluric bacteria. Environ. Microbiol. 17, 913-930 (2015).
7. Finley, R. L. et al. The scourge of antibiotic resistance: the important role of the environment. Clin. Infect. Dis. 57, 704-710 (2013).
8. Forsberg, K. J. et al. The shared antibiotic resistome of soil bacteria and human pathogens. Science 337, 1107-1111 (2012).
9. D'Costa, V. M. et al. Antibiotic resistance is ancient. Nature 477, 457-461 (2011).
10. Andersson, D. I. & Hughes, D. Persistence of antibiotic resistance in bacterial populations. FEMS Microbiol. Rev. 35, 901-911 (2011).
11. Cox, G. & Wright, G. D. Intrinsic antibiotic resistance: mechanisms, origins, challenges and solutions. Int. J. Med. Microbiol. 303, 287-292 (2013).
12. Fajardo, A. et al. The neglected intrinsic resistome of bacterial pathogens. PLoS ONE 3, e1619 (2008).
13. Abraham, E. P. & Chain, E. An enzyme from bacteria able to destroy penicillin. Nature 146, 837 (1940).
14. Davies, J. & Davies, D. Origins and evolution of antibiotic resistance. Microbiol. Mol. Biol. Rev. 74, 417-433 (2010).
15. Fischbach, M. A. & Walsh, C. T. Antibiotics for emerging pathogens. Science 325, 1089-1093 (2009).
16. Lewis, K. Antibiotics: recover the lost art of drug discovery. Nature 485, 439-440 (2012).
17. Cho, H., Uehara, T. & Bernhardt, T. G. β-Lactam antibiotics induce a lethal malfunctioning of the bacterial cell wall synthesis machinery. Cell 159, 1300-1311 (2014).
18. Wilson, D. N. Ribosome-targeting antibiotics and mechanisms of bacterial resistance. Nature Rev. Microbiol. 12, 35-48 (2014).
19. Demirci, H. et al. A structural basis for streptomycin-induced misreading of the genetic code. Nature Commun. 4, 1355 (2013).
20. Dwyer, D. J., Collins, J. J. & Walker, G. C. Unraveling the physiological complexities of antibiotic lethality. Annu. Rev. Pharmacol. Toxicol. 55, 313-332 (2015).
21. Macarron, R. et al. Impact of high-throughput screening in biomedical research. Nature Rev. Drug Discov. 10, 188-195 (2011).
22. Fleischmann, R. D. et al. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 269, 496-512 (1995).
23. Kobayashi, K. et al. Essential Bacillus subtilis genes. Proc. Natl Acad. Sci. USA 100, 4678-4683 (2003).
24. Baba, T. et al. Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol. Syst. Biol. 2, 2006.0008 (2006).
25. Forsyth, R. A. et al. A genome-wide strategy for the identification of essential genes in Staphylococcus aureus. Mol. Microbiol. 43, 1387-1400 (2002).
26. Jacobs, M. A. et al. Comprehensive transposon mutant library of Pseudomonas aeruginosa. Proc. Natl Acad. Sci. USA 100, 14339-14344 (2003).
27. Jain, P. et al. Specialized transduction designed for precise high-throughput unmarked deletions in Mycobacterium tuberculosis. mBio 5, e01245-14 (2014).
28. Brown, E. D. & Wright, G. D. New targets and screening approaches in antimicrobial drug discovery. Chem. Rev. 105, 759-774 (2005).
29. Payne, D. J., Gwynn, M. N., Holmes, D. J. & Pompliano, D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nature Rev. Drug Discov. 6, 29-40 (2007).
30. Silver, L. L. Challenges of antibacterial discovery. Clin. Microbiol. Rev. 24, 71-109 (2011).
31. Tommasi, R., Brown, D. G., Walkup, G. K., Manchester, J. I. & Miller, A. A. ESKAPEing the labyrinth of antibacterial discovery. Nature Rev. Drug Discov. 14, 529-542 (2015).
32. Farha, M. A. & Brown, E. D. Unconventional screening approaches for antibiotic discovery. Ann. NY Acad. Sci. 1354, 54-66 (2015).
33. D'Elia, M. A., Pereira, M. P. & Brown, E. D. Are essential genes really essential? Trends Microbiol. 17, 433-438 (2009).
34. Joyce, A. R. et al. Experimental and computational assessment of conditionally essential genes in Escherichia coli. J. Bacteriol. 188, 8259-8271 (2006).
35. Nichols, R. J. et al. Phenotypic landscape of a bacterial cell. Cell 144, 143-156 (2011).
36. Hensel, M., Shea, J. E., Gleeson, C., Jones, M. D. & Dalton, E. Simultaneous identification of bacterial virulence genes by negative selection. Science 269, 400-403 (1995).
37. Autret, N. & Charbit, A. Lessons from signature-tagged mutagenesis on the infectious mechanisms of pathogenic bacteria. FEMS Microbiol. Rev. 29, 703-717 (2005).
38. van Opijnen, T. & Camilli, A. Transposon insertion sequencing: a new tool for systems-level analysis of microorganisms. Nature Rev. Microbiol. 11, 435-442 (2013).
39. Turner, K. H., Wessel, A. K., Palmer, G. C., Murray, J. L. & Whiteley, M. Essential genome of Pseudomonas aeruginosa in cystic fibrosis sputum. Proc. Natl Acad. Sci. USA 112, 4110-4115 (2015).
40. Fahnoe, K. C. et al. Non-traditional antibacterial screening approaches for the identification of novel inhibitors of the glyoxylate shunt in Gram-negative pathogens. PLoS ONE 7, e51732 (2012).
41. Zlitni, S., Ferruccio, L. F. & Brown, E. D. Metabolic suppression identifies new antibacterial inhibitors under nutrient limitation. Nature Chem. Biol. 9, 796-804 (2013).
42. Starkey, M. et al. Identification of anti-virulence compounds that disrupt quorum-sensing regulated acute and persistent pathogenicity. PLoS Pathog. 10, e1004321 (2014).
43. Pethe, K. et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nature Med. 19, 1157-1160 (2013).
44. Costanzo, M. et al. The genetic landscape of a cell. Science 327, 425-431 (2010).
45. Ho, Y. et al. Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry. Nature 415, 180-183 (2002).
46. Butland, G. et al. Interaction network containing conserved and essential protein complexes in Escherichia coli. Nature 433, 531-537 (2005).
47. Babu, M. et al. Genetic interaction maps in Escherichia coli reveal functional crosstalk among cell envelope biogenesis pathways. PLoS Genet. 7, e1002377 (2011).
48. Gerdes, K., Christensen, S. K. & Løbner-Olesen, A. Prokaryotic toxin-antitoxin stress response loci. Nature Rev. Microbiol. 3, 371-382 (2005).
49. D'Elia, M. A. et al. Lesions in teichoic acid biosynthesis in Staphylococcus aureus lead to a lethal gain of function in the otherwise dispensable pathway. J. Bacteriol. 188, 4183-4189 (2006).
50. D'Elia, M. A. et al. Probing teichoic acid genetics with bioactive molecules reveals new interactions among diverse processes in bacterial cell wall biogenesis. Chem. Biol. 16, 548-556 (2009).
51. Swoboda, J. G. et al. Discovery of a small molecule that blocks wall teichoic acid biosynthesis in Staphylococcus aureus. ACS Chem. Biol. 4, 875-883 (2009).
52. Wang, H. et al. Discovery of wall teichoic acid inhibitors as potential anti-MRSA β-lactam combination agents. Chem. Biol. 20, 272-284 (2013).
53. Farha, M. A. et al. Inhibition of WTA synthesis blocks the cooperative action of PBPs and sensitizes MRSA to β-lactams. ACS Chem. Biol. 8, 226-233 (2013).
54. Farha, M. A. et al. Antagonism screen for inhibitors of bacterial cell wall biogenesis uncovers an inhibitor of undecaprenyl diphosphate synthase. Proc. Natl Acad. Sci. USA 112, 11048-11053 (2015).
55. Liu, A. et al. Antibiotic sensitivity profiles determined with an Escherichia coli gene knockout collection: generating an antibiotic bar code. Antimicrob. Agents Chemother. 54, 1393-1403 (2010).
56. Tan, C. M. et al. Restoring methicillin-resistant Staphylococcus aureus susceptibility to β-lactam antibiotics. Sci. Transl. Med. 4, 126ra35 (2012).
57. Pathania, R. et al. Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting. Nature Chem. Biol. 5, 849-856 (2009).
58. Brynildsen, M. P., Winkler, J. A., Spina, C. S., Macdonald, I. C. & Collins, J. J. Potentiating antibacterial activity by predictably enhancing endogenous microbial ROS production. Nature Biotechnol. 31, 160-165 (2013).
59. Dwyer, D. J. et al. Antibiotics induce redox-related physiological alterations as part of their lethality. Proc. Natl Acad. Sci. USA 111, E2100-E2109 (2014).
60. Taylor, P. L., Rossi, L., De Pascale, G. & Wright, G. D. A forward chemical screen identifies antibiotic adjuvants in Escherichia coli. ACS Chem. Biol. 7, 1547-1555 (2012).
61. King, A. M. et al. Aspergillomarasmine A overcomes metallo-β-lactamase antibiotic resistance. Nature 510, 503-506 (2014).
62. Borisy, A. A. et al. Systematic discovery of multicomponent therapeutics. Proc. Natl Acad. Sci. USA 100, 7977-7982 (2003).
63. Ejim, L. et al. Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. Nature Chem. Biol. 7, 348-350 (2011).
64. D'Costa, V. M., McGrann, K. M., Hughes, D. W. & Wright, G. D. Sampling the antibiotic resistome. Science 311, 374-377 (2006).
65. Bhullar, K. et al. Antibiotic resistance is prevalent in an isolated cave microbiome. PLoS ONE 7, e34953 (2012).
66. Bérdy, J. Bioactive microbial metabolites. J. Antibiot. 58, 1-26 (2005).
67. Baltz, R. H. Marcel Faber Roundtable: is our antibiotic pipeline unproductive because of starvation, constipation or lack of inspiration? J. Ind. Microbiol. Biotechnol. 33, 507-513 (2006).
68. Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3-26 (2001).
69. O'Shea, R. & Moser, H. E. Physicochemical properties of antibacterial compounds: implications for drug discovery. J. Med. Chem. 51, 2871-2878 (2008).
70. Kim, J., Kim, H. & Park, S. B. Privileged structures: efficient chemical 'navigators' toward unexplored biologically relevant chemical spaces. J. Am. Chem. Soc. 136, 14629-14638 (2014).
71. Galloway, W. R., Bender, A., Welch, M. & Spring, D. R. The discovery of antibacterial agents using diversity-oriented synthesis. Chem. Commun. 2009, 2446-2462 (2009).
72. Rachakonda, V., Alla, M., Kotipalli, S. S. & Ummanni, R. Design, diversity-oriented synthesis and structure activity relationship studies of quinolinyl heterocycles as antimycobacterial agents. Eur. J. Med. Chem. 70, 536-547 (2013).
73. Han, S., Zaniewski, R. P. & Marr, E. S. Structural basis for effectiveness of siderophore-conjugated monocarbams against clinically relevant strains of Pseudomonas aeruginosa. Proc. Natl Acad. Sci. USA 107, 22002-22007 (2010).
74. Eisenstein, B. I., Oleson, F. B. & Baltz, R. H. Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD. Clin. Infect. Dis. 50 (suppl. 1), S10-S15 (2010).
75. Gerber, M. & Ackermann, G. OPT-80, a macrocyclic antimicrobial agent for the treatment of Clostridium difficile infections: a review. Expert Opin. Investig. Drugs 17, 547-553 (2008).
76. Lok, C. Mining the microbial dark matter. Nature 522, 270-273 (2015).
77. Wilson, M. C. et al. An environmental bacterial taxon with a large and distinct metabolic repertoire. Nature 506, 58-62 (2014).
78. Ling, L. L. et al. A new antibiotic kills pathogens without detectable resistance. Nature 517, 455-459 (2015).
79. Brown, E. D. Is the GAIN Act a turning point in new antibiotic discovery? Can. J. Microbiol. 59, 153-156 (2013).
80. Spellberg, B., Bartlett, J., Wunderink, R. & Gilbert, D. N. Novel approaches are needed to develop tomorrow's antibacterial therapies. Am. J. Respir. Crit. Care Med. 191, 135-140 (2015).
81. Spellberg, B. The future of antibiotics. Crit. Care 18, 228 (2014).
82. McArthur, A. G. & Wright, G. D. Bioinformatics of antimicrobial resistance in the age of molecular epidemiology. Curr. Opin. Microbiol. 27, 45-50 (2015).
83. 3D. Nature Protoc. 4, 1535-1550 (2009).